PAR14 COST MINIMIZATION ANALYSIS OF RITUXIMAB VERSUS INFLIXIMAB, ADALIMUMAB AND ETANERCEPT FOR RHEUMATOID ARTHRITIS FROM A PAYER PERSPECTIVE IN BRAZIL

Nov 1, 2007, 00:00
10.1016/S1098-3015(10)64929-7
https://www.valueinhealthjournal.com/article/S1098-3015(10)64929-7/fulltext
Title : PAR14 COST MINIMIZATION ANALYSIS OF RITUXIMAB VERSUS INFLIXIMAB, ADALIMUMAB AND ETANERCEPT FOR RHEUMATOID ARTHRITIS FROM A PAYER PERSPECTIVE IN BRAZIL
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)64929-7&doi=10.1016/S1098-3015(10)64929-7
First page :
Section Title :
Open access? : No
Section Order : 89
Categories :
Tags :
Regions :
ViH Article Tags :